Foresite Capital recently announced Molly as its venture partner. Molly previously worked at Illumina as a senior director. Molly is quite instrumental to Foresite Capital because he has over fifteen years of experience in genomic research and development. Jim Tananbaum, who is the CEO and MD of Foresite Capital said that Dr. Molly is among the most respected research scientists in next generation sequencing. Jim added that Molly will be invaluable to ForeSite Capital as the company continues to diversify and expand its portfolio.
Dr. Molly was a senior scientific research director at Illumina. Molly played a significant role in Illumina’s global protein reagent improvements and innovation. Before Joining Illumina, Molly worked at Pacific Biosciences. Molly also spent one decade focusing on drugs that target immune diseases and cancer and developing antibodies. Molly attended Nankai University and University of California where she graduated with a degree in biochemistry and a Ph.D in protein biophysics respectively. Molly also has over twenty patent applications and has published over twenty papers.
Molly said on Bloomberg that she was excited to join Foresite Capital due to its reputation of its innovative products and services. Molly added that she feels honored to join a dynamic team of professionals to grow Foresite’s portfolio. Foresite Capital aims at improving drug recovery and clinical research strategies.
Foresite Capital plays a significant role in providing capital for the growth of healthcare leaders. The company provides disruptive services and products in all healthcare fields in both public and private markets. Foresite Capital has its headquarters in San Francisco.
Jim Tananbaum attained his M.D in Harvard School of Medicine. Additionally, Jim, graduated with B.S.E.E and B.S from Yale University. Jim has gained success in most of his ventures. For instance, he was the head of investments in twenty one health care companies including notable ones such as Amira and Amerigroup Pharmaceuticals.